Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 6, 2011	Here's What Icahn Capital Bought and Sold Last Quarter Carl Icahn is CEO of Icahn Capital, which is a privately owned hedge fund sponsor that invests in small- and medium-sized companies having undervalued share prices. Let's take a look at their recent moves.
The Motley Fool February 23, 2010 Brian Orelli	Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year.
InternetNews March 24, 2008	Icahn Sues Motorola to Get Access to Documents Investor Carl Icahn said on Monday he is suing Motorola to force it to hand over documents related to its mobile devices business, and he urged investors to elect his slate of candidates to the Motorola board.
The Motley Fool June 10, 2010 Brian Orelli	Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday.
The Motley Fool November 18, 2008 Brian Orelli	Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere.
The Motley Fool March 23, 2010 Brian Orelli	Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next?
The Motley Fool June 4, 2009 Brian Orelli	Ignore Icahn's Hoopla Carl Icahn and his fights with management at Biogen's Idec make for entertaining news coverage, but investors shouldn't spend too much time analyzing how the antics are going to affect the share price.
InternetNews March 26, 2008	Motorola to Split Into Two Motorola said on Wednesday it would split into two publicly traded entities to separate its loss-making handset division from its other businesses.
The Motley Fool September 15, 2008 Brian Orelli	Side Effects Don't Scare Icahn Billionaire investor Carl Icahn upped his stake in the drug company by almost 50% and now owns 7.3% of the company.
The Motley Fool January 29, 2010 Brian Orelli	Icahn Back to Batter Biogen The old guy has tenacity.
InternetNews January 30, 2007 Ed Sutherland	Icahn Has Motorola in His Sites News Wall Street trader Carl Icahn wants a spot on Motorola's board sent tongues wagging and stock prices up.
The Motley Fool October 4, 2006 Brian Lawler	Unwelcome Guests at ImClone ImClone's board of directors votes against Carl Icahn's proposed removal of six company directors. Short-term shareholders that are able to cash out with Icahn, will possibly have a nice gain to take home.
The Motley Fool October 14, 2011 Travis Hoium	Navistar International Shares Popped: What You Need to Know Shares of Navistar International drove as much as 16% higher today before dropping to a more modest gain of 8% mid-day.
National Real Estate Investor December 4, 2002 Parke Chapman	Investor now holds 6.9% stake in Insignia Carl Icahn now holds a 6.9% stake in real estate operator Insignia Financial Group Inc.
BusinessWeek October 29, 2007 Hamm & Grover	Tech Gets the Icahn Treatment Carl Icahn is shaking up the landscape in Silicon Valley as companies' revenue growth slows.
The Motley Fool January 29, 2008 Brian Lawler	Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec.
InternetNews March 24, 2008 Judy Mottl	Icahn Challenges Motorola on Handheld Strategy Motorola stockholder and longtime critic Carl Icahn is seeking answers about the company's floundering performance, filing a lawsuit today seeking documents related to Moto's beleaguered mobile device division.
The Motley Fool November 30, 2010 Tim Beyers	Carl Icahn Is Right Shares of Motorola trade for 15 times next year's estimated normalized earnings, which are expected to grow more than 40%. That's too cheap a price.
The Motley Fool July 23, 2008 Rick Aristotle Munarriz	Icahn's Spotty Track Record Carl Icahn and Yahoo! have made nice, in advance of next week's meeting, but will the peace last? Or is the current calm just the eye of the hurricane?
The Motley Fool May 13, 2009 Brian Orelli	Icahn's an Energizer Pit Bull He keeps going and doesn't let go.
The Motley Fool April 8, 2010 Brian Orelli	Is Icahn Stuck in the Station? Saving Genzyme's train wreck may be difficult.
The Motley Fool January 30, 2009 Brian Orelli	Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%.
BusinessWeek March 5, 2007 Ronald Grover	Just Don't Call Him A Raider Carl Icahn, who now styles himself a shareholder activist, prepares for battle with Motorola.
BusinessWeek April 9, 2007 Roben Farzad	Activist Investors Not Welcome Activist hedge fund manager Carl C. Icahn's interference at Motorola stands in the way of its mission.
The Motley Fool May 19, 2008 Brian Orelli	What Will Icahn Do With Amylin? Carl Icahn recently took an initial position now worth around $200 million in Amylin Pharmaceuticals, and stockholders must be wondering about his motivation for the purchase.
BusinessWeek March 6, 2006 Ronald Grover	Carl Icahn: Still An Improbable Robin Hood Carl Icahn is out to recast himself as the hedge fund investor's champion. That image has its critics.
The Motley Fool November 23, 2004 Charly Travers	Mylan's "Three-Ring Circus" Carl Icahn is involved in the Mylan-King Pharmaceuticals so he can manipulate this situation to make money. And a lot of it.
The Motley Fool June 11, 2008 Brian Lawler	He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head.
The Motley Fool December 15, 2010 Toby Shute	This Corporate Raider Hasn't Lost His Touch Has Carl Icahn outsmarted Blackstone with his bid for utility company Dynegy? The tentative answer today appears to be yes.
The Motley Fool August 22, 2011 Dan Radovsky	Should Icahn's Interest in Clorox Perk Yours? Does corporate raider Carl Icahn want to clean Clorox's house for himself, or does he just want to flip it for a quick profit?
The Motley Fool September 1, 2009 Rick Aristotle Munarriz	Icahn Handles the Truth at Yahoo! Carl Icahn has sold shares of struggling online giant Yahoo! in each of the past three trading days, enough to take his stake below 5%.
The Motley Fool December 21, 2010 Toby Shute	Chesapeake Energy in the Crosshairs What's this activist investor got planned for the energy titan?
InternetNews February 11, 2008	Motorola, Nortel in Talks to Combine Units: Report Motorola and Nortel Networks are in talks to combine their wireless infrastructure units.
The Motley Fool July 22, 2011 Evan Niu	Clorox to Icahn: "It's Not You, It's Me" Clorox announces that its board has unanimously rejected Icahn's unsolicited bid to acquire the company.
The Motley Fool June 15, 2010 Ryan McBride	Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week.
InternetNews January 4, 2011	Motorola Finalizes Mobile Split Telecommunications stalwart concludes its division into Motorola Solutions and Motorola Mobility, focusing on enterprise equipment and consumer devices, respectively.
The Motley Fool February 8, 2005 Tom Taulli	Retro Raider Strikes Again Carl Icahn has been very busy lately -- and his most recent prey is cardboard packaging manufacturer Temple-Inland. The stock closed unchanged yesterday at $75.75. It had surged 16% when his interest in the stock became public.
The Motley Fool September 21, 2006 Brian Lawler	ImClone's Board Shakeup A new face in the boardroom heralds change for the troubled company. Shareholders yesterday elected notorious corporate raider Carl Icahn to the company's board of directors.
The Motley Fool February 6, 2009 Brian Orelli	Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board.
The Motley Fool September 24, 2008 Brian Lawler	Bristol-Myers Puts Icahn and ImClone to the Test Despite trying to project different intentions last week, pharma giant Bristol-Myers Squibb raised its bid for ImClone Systems.
The Motley Fool February 17, 2006 Rick Aristotle Munarriz	A Time for Peace Carl Icahn appears to have come to a truce with Time Warner over his breakup plans. However, a significant show of shareholders siding with Icahn's nominees may also force Time Warner to take a harder look at why it can't seem to get its stock out of the high teens.
The Motley Fool May 16, 2008 Mac Greer	Fool Video: Icahn Bares His Teeth, Craig's Cyst, and 5 Stocks Approaching Greatness Can Craigslist delete eBay? Will Icahn deliver for Microsoft? These questions are discussed in this video.
The Motley Fool June 16, 2010 Ryan McBride	Genzyme Annual Meeting Remarkably Mundane, Despite Rocky Year Genzyme's annual meeting was over in about an hour, and although the company took some hard questions from a shareholder, it appears that chairman and CEO Henri Termeer and the rest of the company's directors were easily reelected to serve on the board of directors.
The Motley Fool March 30, 2011 Anders Bylund	Mentor Could Use Some Guidance Is the company looking to preserve shareholder interest or management paychecks?
The Motley Fool October 27, 2010 Selena Maranjian	When Hostile Takeovers Get Ugly Conflict between companies and potential buyers can spill over to hurt shareholders.
The Motley Fool May 29, 2008 Brian Lawler	Icahn Girds for Biogen Battle The activist investor officially launches his bid to usurp Biogen's board of directors.
The Motley Fool February 17, 2010 Anders Bylund	Who Is Icahn Selling To Now? Lionsgate is looking to buy the Miramax studio from Walt Disney in what looks like a good stylistic match. Will Carl Icahn turn the tables on that deal and coax a bid out of Disney?
InternetNews March 26, 2008 Judy Mottl	Will Motorola Split Reverse Decline? Motorola today said it plans to split its core mobile devices and broadband businesses into two publicly-owned companies.
The Motley Fool August 20, 2010 Brian Orelli	This Billionaire Likes Biotech. Should You? It depends on how much you trust management.
The Motley Fool April 15, 2005 Tom Taulli	Carl Icahn Strikes Again Energy and inorganic-chemical company Kerr-McGee and investor Icahn make peace. The market's happy, and Icahn's war chest just gets bigger.